PRETREATMENT WITH SOMATOSTATIN ANALOG SMS 201-995 POTENTIATES GROWTH-HORMONE (GH) RESPONSIVENESS TO GH-RELEASING FACTOR IN SHORT CHILDREN

被引:19
作者
DICKERMAN, Z
GUYDA, H
TANNENBAUM, GS
机构
[1] MONTREAL CHILDRENS HOSP, DIV ENDOCRINOL & METAB, 2300 TUPPER ST, ROOM D-371, MONTREAL H3H 1P3, QUEBEC, CANADA
[2] MONTREAL CHILDRENS HOSP, DIV NEUROL, MONTREAL H3H 1P3, QUEBEC, CANADA
[3] MCGILL UNIV, DEPT PEDIAT, MONTREAL H3A 2T5, QUEBEC, CANADA
[4] MCGILL UNIV, DEPT NEUROL & NEUROSURG, MONTREAL H3A 2T5, QUEBEC, CANADA
[5] MCGILL UNIV, DEPT MED, MONTREAL H3A 2T5, QUEBEC, CANADA
关键词
D O I
10.1210/jc.77.3.652
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Previous studies in children have shown inconsistent, poorly reproducible GH responses to exogenous GH-releasing factor (GRF), with wide individual variability. In the present study, we tested the hypothesis that prior administration of the long-acting somatostatin analog, SMS 201-995 (SMS), will enhance GH responsiveness to a subsequent GRF challenge. Two study protocols were employed in 37 children with short stature [M = 31, F = 6, ages 11.8 +/- 1.6 yr (mean +/- SEM), height -2.25 +/- 0.55 SDS (SD scores)]. In both studies, each subject served as his/her own control. In the first study, which was designed to determine optimal SMS dose and regimen, SMS, in doses ranging from 0.8-2.2 mug/kg sc, was randomly administered or omitted at 0800 h after an overnight fast, and a GRF bolus (50 mug, iv) was given 4 h later. In the second study, we employed a protocol identical to study 1 except for the use of standard doses of SMS (1 mug/kg, sc) and GRF (1 mug/kg, iv) and an additional 1-h delay of the GRF injection. Plasma GH levels were measured every 20 min from 0800 h until 2 h after the GRF injection in both studies. In study 1 (n = 12; M = 10, F = 2), SMS significantly suppressed spontaneous GH secretion (expressed as the mean +/- SEM GH AUC during the 4-h SMS-GRF interval, AUC 1: 2.2 +/- 0.4 vs. 6.2 +/- 0.9 mug/L.h; P < 0.001), GH responsiveness to GRF (GH AUC during the 2 h after the GRF injection, AUC 2: 41.5 +/- 7.8 vs. 85.0 +/- 13.5 mug/L.h; P < 0.001), and the GH peak response (17.4 +/- 3.1 vs. 36.0 +/- 6.2 mug/L; P < 0.001), compared to control tests. In contrast, in study 2 (n = 25; M = 21, F = 4), whereas spontaneous GH secretion was still suppressed during the 5-h SMS-GRF interval (AUC 103.8 +/- 0.4 vs. 7.4 +/- 1.1 mug/L.h, P < 0.001), both the GH peak response (56.7 +/- 5.5 vs. 30.5 +/- 3.0 mug/L; P < 0.0001) and the GH AUC (AUC 2:103.7 +/- 10.3 vs. 77.5 +/- 6.8 mug/L.h; P < 0.05) after GRF administration significantly augmented by pretreatment with SMS, compared to control tests. Taken together these results indicate that a priming SMS dose of 1 mug/kg has a significant permissive effect on GH responsiveness to exogenous GRF administered 5 h later. The combined SMS-GRF test may facilitate the discrimination between normal short children and those with truly diminished GH secretion.
引用
收藏
页码:652 / 657
页数:6
相关论文
共 38 条
[1]  
[Anonymous], 1959, RADIOGRAPH ATLAS SKE
[2]   GROWTH HORMONE-RELEASING HORMONE-SYNTHESIZING NEURONS ARE A SUBPOPULATION OF SOMATOSTATIN RECEPTOR-LABELED CELLS IN THE RAT ARCUATE NUCLEUS - A COMBINED INSITU HYBRIDIZATION AND RECEPTOR LIGHT-MICROSCOPIC AUTORADIOGRAPHIC STUDY [J].
BERTHERAT, J ;
DOURNAUD, P ;
BEROD, A ;
NORMAND, E ;
BLOCH, B ;
ROSTENE, W ;
KORDON, C ;
EPELBAUM, J .
NEUROENDOCRINOLOGY, 1992, 56 (01) :25-31
[3]  
BUTENANDT O, 1989, ACTA PAEDIATR SCAND, P93
[4]   THE GROWTH-HORMONE (GH)-RELEASING HORMONE (GHRH)-GH-SOMATOMEDIN AXIS - EVIDENCE FOR RAPID INHIBITION OF GHRH-ELICITED GH RELEASE BY INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II [J].
CEDA, GP ;
DAVIS, RG ;
ROSENFELD, RG ;
HOFFMAN, AR .
ENDOCRINOLOGY, 1987, 120 (04) :1658-1662
[5]  
CHATELAIN P, 1987, J CLIN ENDOCR METAB, V65, P387
[6]   MEDICAL-TREATMENT OF ACROMEGALY WITH SMS 201-995, A SOMATOSTATIN ANALOG - A COMPARISON WITH BROMOCRIPTINE [J].
CHIODINI, PG ;
COZZI, R ;
DALLABONZANA, D ;
OPPIZZI, G ;
VERDE, G ;
PETRONCINI, M ;
LIUZZI, A ;
DELPOZO, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 64 (03) :447-453
[7]  
Cho Kyoo Hong, 1992, Journal of Pediatric Endocrinology, V5, P155
[8]   SOMATOSTATIN PARTIALLY REVERSES DESENSITIZATION OF SOMATOTROPHS INDUCED BY GROWTH HORMONE-RELEASING FACTOR [J].
CLAYTON, RN ;
BAILEY, LC .
JOURNAL OF ENDOCRINOLOGY, 1987, 112 (01) :69-76
[9]   GROWTH-HORMONE SECRETORY DYNAMICS IN SUBJECTS WITH NORMAL STATURE [J].
COSTIN, G ;
KAUFMAN, FR ;
BRASEL, JA .
JOURNAL OF PEDIATRICS, 1989, 115 (04) :537-544
[10]   ENDOCRINE PROFILE OF A LONG-ACTING SOMATOSTATIN DERIVATIVE SMS-201-995 - STUDY IN NORMAL VOLUNTEERS FOLLOWING SUBCUTANEOUS ADMINISTRATION [J].
DELPOZO, E ;
NEUFELD, M ;
SCHLUTER, K ;
TORTOSA, F ;
CLARENBACH, P ;
BIEDER, E ;
WENDEL, L ;
NUESCH, E ;
MARBACH, P ;
CRAMER, H ;
KERP, L .
ACTA ENDOCRINOLOGICA, 1986, 111 (04) :433-439